Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Clinically relevant pharmacogenomic findings are seen in single nucleotide polymorphism (SNP) genotyping and exome sequencing data…
From - Diagnostic Testing & Emerging Technologies
Reference pricing is associated with nearly a one-third reduction in the average price paid for 285 different types of tests, according to a…
From - Diagnostic Testing & Emerging Technologies
Health care corporate venture capital (CVC) is increasing across all sectors of the industry in terms of number of deals, dollars invested, and number of…
From - Diagnostic Testing & Emerging Technologies
The United States has the screening capacity to meet colorectal screening goals, but this capacity has so far not translated into increased screening rates, according to a…